NCT07042893

Brief Summary

Lung resection is associated with high postoperative morbidity and mortality and leads to a significant long-term decrease in functional capacity, particularly due to cardiorespiratory complications. One of the contributing factors to this functional decline is the postoperative reduction in right ventricular function. Due to the anatomical proximity and interactions, right ventricular function is evaluated by echocardiography following lung resection. The pulmonary artery pressure (PAP)/tricuspid annular plane systolic excursion (TAPSE) ratio is a parameter that provides a more comprehensive assessment of right heart function by evaluating both right ventricular systolic function and pulmonary artery pressure. In this study, investigators aimed to evaluate changes in right heart function by performing preoperative and postoperative echocardiographic assessments in participants undergoing lung resection, focusing on PAP/TAPSE ratios.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
33

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Apr 2025

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2025

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

June 20, 2025

Completed
9 days until next milestone

First Posted

Study publicly available on registry

June 29, 2025

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 24, 2026

Completed
21 days until next milestone

Study Completion

Last participant's last visit for all outcomes

May 15, 2026

Completed
Last Updated

May 26, 2026

Status Verified

May 1, 2026

Enrollment Period

1.1 years

First QC Date

June 20, 2025

Last Update Submit

May 22, 2026

Conditions

Keywords

pulmonary resectionright ventricular functionechocardiographycardiothoracic anesthesia

Outcome Measures

Primary Outcomes (3)

  • Echocardiographic Assessment: TAPSE/PAP Ratio

    Patients will be evaluated by echocardiography 24 hours before surgery and on the second postoperative day, and the TAPSE/PAP ratio will be recorded in mm/mmHg.

    24 hours preoperatively and on postoperative day 2

  • Echocardiographic Assessment: Tricuspid Annular Plane Systolic Excursion (TAPSE)

    Patients will be evaluated by echocardiography 24 hours preoperatively and on postoperative day 2, and TAPSE will be recorded in millimeters (mm).

    24 hours preoperatively and on postoperative day 2

  • Echocardiographic Assessment: Pulmonary Artery Pressure (PAP)

    Patients will be evaluated by echocardiography 24 hours before surgery and on the second postoperative day, and PAP will be recorded in millimeters of mercury (mmHg).

    24 hours preoperatively and on postoperative day 2

Study Arms (1)

Group 1

In this study, a single group (Group 1) will be defined, and patients scheduled for lung resection who agree to participate will be included.

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients aged 18 to 80 years scheduled to undergo lung resection surgery.

You may qualify if:

  • Adults aged 18 to 80 years
  • ASA classification I-III
  • Patients scheduled to undergo lung resection in thoracic surgery

You may not qualify if:

  • Patients with arrhythmia
  • Patients using antiarrhythmic drugs
  • Patients with renal failure requiring hemodialysis
  • Patients with a history of previous lung surgery
  • Patients with valvular heart disease
  • Patients with a history of angina pectoris or myocardial infarction within the past month
  • Patients with FEV1/FVC ratio below 60%

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Gazi University Faculty of Medicine, Ankara

Ankara, Yenimahalle, 06500, Turkey (Türkiye)

Location

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
asst. prof.

Study Record Dates

First Submitted

June 20, 2025

First Posted

June 29, 2025

Study Start

April 1, 2025

Primary Completion

April 24, 2026

Study Completion

May 15, 2026

Last Updated

May 26, 2026

Record last verified: 2026-05

Data Sharing

IPD Sharing
Will not share

Locations